Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies

To date, the RV144 HIV vaccine trial has been the only study to show that immunization can confer protection from HIV infection. While encouraging, the modest 31.2% (P = 0.04) efficacy achieved in this study left significant room for improvement, and created an incentive to optimize the AIDSVAX B/E...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:PLoS One
Autori principali: Doran, Rachel C., Tatsuno, Gwen P., O’Rourke, Sara M., Yu, Bin, Alexander, David L., Mesa, Kathryn A., Berman, Phillip W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916523/
https://ncbi.nlm.nih.gov/pubmed/29689099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0196370
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi